Genentech Gets OK To Discuss Confirmatory Study Plans At Avastin Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA hearing officer Karen Midthun rejects the Center for Drug Evaluation and Research's request to bar evidence on discussions over a new study of Avastin in first-line metastatic breast cancer.
You may also be interested in...
Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer
Genentech is counting on biomarker data gathered across the Avastin development program – in addition to a new assay developed by parent company Roche – to help it retain the VEGF inhibitor’s accelerated approval in metastatic breast cancer.
Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer
Genentech is counting on biomarker data gathered across the Avastin development program – in addition to a new assay developed by parent company Roche – to help it retain the VEGF inhibitor’s accelerated approval in metastatic breast cancer.
Avastin Breast Cancer Dispute Centers On “Magnitude Of Benefit” Questions
The decision on whether Avastin’s metastatic breast cancer indication should be retained may come down to three words – “magnitude of benefit.”